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ABSTRACT
Objectives: A steady increase in the prevalence of
autism spectrum disorders (ASD) has been reported in
studies based on different methods, requiring
adjustment for participation and missing data. Recent
studies with high ASD prevalence rates rarely report on
co-occurring medical conditions. The aim of the study
was to describe the prevalence of clinically confirmed
cases of ASD in Iceland and concomitant medical
conditions.
Design: The cohort is based on a nationwide database
on ASD among children born during 1994–1998.
Participants: A total of 267 children were diagnosed
with ASD, 197 boys and 70 girls. Only clinically
confirmed cases were included. All received physical
and neurological examination, standardised diagnostic
workup for ASD, as well as cognitive testing. ASD
diagnosis was established by interdisciplinary teams.
Information on medical conditions and chromosomal
testing was obtained by record linkage with hospital
registers.
Setting: Two tertiary institutions in Iceland. The
population registry recorded 22 229 children in the
birth cohort.
Results: Prevalence of all ASD was 120.1/10 000
(95% CI 106.6 to 135.3), for boys 172.4/10 000
(95% CI 150.1 to 198.0) and for girls 64.8/10 000
(95% CI 51.3 to 81.8). Prevalence of all medical
conditions was 17.2% (95% CI 13.2 to 22.2),
including epilepsy of 7.1% (95% CI 4.6 to 10.8). The
proportion of ASD cases with cognitive impairment
(intellectual quotient <70) was 45.3%, but only 34.1%
were diagnosed with intellectual disability (ID).
Children diagnosed earlier or later did not differ on
mean total score on a standardised interview for
autism.
Conclusions: The number of clinically verified cases
is larger than in previous studies, yielding a prevalence
of ASD on a similar level as found in recent non-
clinical studies. The prevalence of co-occurring medical
conditions was high, considering the low proportion of
ASD cases that also had ID. Earlier detection is clearly
desirable in order to provide counselling and treatment.
INTRODUCTION
The earliest epidemiological studies on the
prevalence of autism-reported ﬁgures are in
the range of 3–5/10 000. In the 1980s, there
was some evidence of an increased prevalence
of autism, but since the early 90s a steady
increase has been apparent.1 In a recent
review of 43 studies, which provided estimates
for the prevalence of autism and pervasive
developmental disorders (PDDs), 19 were
classiﬁed as newer epidemiological surveys of
PDDs.2 These were published between 2000
and 2008 and covered the ages 0–17 years.
The prevalence ﬁgures were in the range of
30.0–67.4/10 000 except in two studies, one
ARTICLE SUMMARY
Article focus
▪ Information on the prevalence of autism spec-
trum disorders (ASD) is important for effective
service planning.
▪ Increases in the prevalence of ASD have been
found by different methods, and the procedures
have required adjustments for low response rate
or missing data. High rates of ASD need to be
confirmed in studies based on clinical cases in
well-defined populations.
Key messages
▪ A high prevalence rate based on clinically verified
cases of ASD was found in a nationwide birth
cohort and is, on average, comparable to that in
recent studies.
▪ Hospital registries ensured accurate rates of
co-occurring medical conditions and chromo-
somal aberrations.
▪ Although the service and health care system
diagnosed a fair number of autism cases, earlier
detection is needed in order to provide counsel-
ling and treatment.
Strengths and limitations of this study
▪ The population is well defined and relatively
homogenous. Good record keeping, easy access
to healthcare, education free of charge and the
comprehensive social system have all ensured
efficient case finding at tertiary institutions.
▪ Case finding was based on the presence of ASD
in the records at tertiary level services. Thus, the
prevalence found should be regarded as the
minimum figures.
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in South Thames (UK) with a prevalence of 116.1/
10 0003 and another from Toyota ( Japan) with a preva-
lence of 181.1/10 000.4 More recent studies have
reported an even higher prevalence, 157/10 000
and 260/10 000.5 6 Whether this increase in prevalence
over the decades reﬂects a true increase in incidence or
is due to different methodological factors is a matter of
debate.2 5
From the ﬁrst prevalence studies on autism to the
present, few studies have dealt with co-occurring
medical conditions, some of which have been reviewed
recently.7 In studies involving the whole autism spec-
trum, medical conditions are rarely reported.2
In this study, we present the prevalence of autism spec-
trum disorders (ASD) in a birth cohort of an entire
nation with a clinical ascertainment of all cases at a ter-
tiary institute. Co-occurring medical conditions of neu-
rodevelopmental origin obtained from hospital registers
are reported.
METHODS
This prevalence study was performed at the State
Diagnostic and Counselling Centre (SDCC), which is a
tertiary institute, serving children with serious neurode-
velopmental disorders in Iceland, and has had the
responsibility of ASD diagnostics and services since 1997.
For the purpose of this study, a database on ASD was
kept at SDCC.
The healthcare system, the educational system and
social services in Iceland are ﬁnanced by governmental
taxes and all residents are covered by national health
insurance schemes and these services have an important
role in case ﬁnding and referrals. Primary healthcare
centres manage a comprehensive maternity and child-
care plan. The child health and developmental surveil-
lance includes 11 visits during the preschool years to a
general practitioner/paediatrician or a nurse where the
children are vaccinated and clinically evaluated. The vac-
cination schedule includes the pertussis/diphtheria/
tetanus immunisation, which covers 97% of the children
and the ﬁrst measles/mumps/rubella immunisation at
the age of 18 months, which covers more than 92%
according to the Chief Epidemiologist.8 The ﬁrst contact
with the educational system is through preschool
services, which are attended by approximately 90% of
children.9 Education is compulsory for children aged
6–16 years, and includes special educational needs. The
social services provide ﬁnancial support to parents of
children with serious developmental disorders or long-
term illnesses, based on medical certiﬁcate.
Two specialised tertiary centres formally diagnose
autism and ASD: the SDCC and the Department of
Child and Adolescent Psychiatry at the Landspitali
University Hospital (LUH), and records from the latter
are included in the database of ASD at SDCC. An inter-
disciplinary team consisting of paediatricians or child
psychiatrists, clinical child psychologists and social
workers reach consensus on the clinical diagnoses.
Other professionals involved in the diagnostic workup
include speech and language pathologists, special tea-
chers and occupational therapists.
All the children in the study underwent a physical
examination and a neurological evaluation. The Autism
Diagnostic Interview-Revised (ADI-R)10 and the Autism
Diagnostic Observation Schedule (ADOS)11 were admi-
nistered, as well as cognitive tests and tests evaluating
adaptive behaviour. Of the children classiﬁed as ASD
cases, 94% received ADI-R and 87.6%, ADOS. All
received either ADI-R or ADOS. The intellectual quo-
tient (IQ) or developmental quotient data, henceforth
both referred to as IQ, were available for all the children
and assessment of adaptive behaviour for 88.3% of chil-
dren. The diagnoses were based on the above informa-
tion as well as other information from hospitals, schools
and the referral services. The majority of children diag-
nosed early during the preschool years were reassessed
before beginning elementary school at 6 years of age.12
The classiﬁcation of autism and ASD was based on the
International Classiﬁcation of Diseases (ICD)-10.13 To
facilitate comparison with DSM-IV,14 three diagnostic cat-
egories are reported: childhood autism (CA) ICD-10
F84.0 (DSM-IV Autistic Disorder), Asperger’s Syndrome
(AS) ICD-10 F84.5 (DSM-IV Asperger’s Disorder) and
other ASD including ICD-10 F84.1, F84.8 and F84.9
(DSM-IV PDD, not otherwise speciﬁed). The ICD-10
F84.4 code was not used.
Cognitive ability was classiﬁed into three levels, IQ<50,
50–69, 70+, and cognitive impairment was deﬁned as
IQ<70. The diagnosis of intellectual disability (ID) was
established according to ICD-10 criteria, taking into
account the total score on standardised intellectual or
developmental tests,15–19 the pattern of abilities, as well
as measures of adaptive behaviour20 21 and other rele-
vant information. Diagnosis of ID was made only after
two successive cognitive tests.
As ASD is thought to result from a neurological abnor-
mality, co-occurring medical conditions with neurodeve-
lopmental underpinnings were collected. Based on the
personal identiﬁer, a record linkage was made between
the ASD database and the electronic database contain-
ing all discharge diagnoses at LUH, thus obtaining
access to all medical diagnoses of these children up to
the end of 2009. For increased precision of the medical
data, we double-checked information regarding genetic
testing by linking the personal identiﬁer of the ASD
cases to the records of the Department of Cytogenetics,
LUH. The genetic testing and the related results were a
product of different routine tests used for clinical evalu-
ation over the years. A paediatrician (IG) selected the
medical conditions to be reported from diagnoses
obtained by record linkage with the hospital registry and
the records at SDCC. This was carried out by taking into
consideration neurological abnormalities, neurodevelop-
mental conditions, genetic and congenital syndromes,
and epilepsy without assuming an aetiological role
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between the condition and ASD for the individual case.7
The deﬁnition of epilepsy was two unprovoked seizures.
For the calculation of prevalence, the numerator was
children pertaining to the 1994–1998 cohort diagnosed
with ASD, while the denominator was all children born
in Iceland during this period and residing in Iceland at
the end of 2009, in total 22 229, 11 424 males and
10 805 females according to the National Registry.22 A
calculation of 95% CI was based on a method proposed
by Wilson.23 A comparison was made between the group
diagnosed by the end of 2005 and the group diagnosed
during 2006 and 2009. A χ2 test was used to compare
groups for categorical variables and a t test for differ-
ences in means. All p values were two tailed and consid-
ered statistically signiﬁcant at a p value less than 0.05.
The study was approved by the Data Protection
Authority, the National Bioethics Committee
(VSNb2009100017/03.1) and the Scientiﬁc Committee
of LUH.
RESULTS
Among the birth cohort 1994–1998, a total of 267 chil-
dren were diagnosed with ASD, 197 males and 70
females. Table 1 shows the prevalence of ASD diagnoses,
as well as the male/female ratio, cognitive level and the
number of children with medical conditions. The overall
prevalence was 120.1 (95% CI 106.6 to 135.3); the preva-
lence for boys was 172.4/10 000 (95% CI 150.1 to 198.0)
and for girls it was 64.8/10 000 (95% CI 51.3 to 81.8).
Of the cases, 17.2% tested below IQ 50, 28.1% in the
50–69 range, and 54.7% tested ≥70. The mean IQ for all
ASD cases was 72.84 (SD=23.90, range<20–134), for
boys 74.44 (SD=23.74), and for girls 68.31 (SD=23.91),
t(265)=1.85, p=0.065. The male/female ratio was 2.1 for
children with cognitive impairment (IQ<70) and 3.7 for
those without such impairment, χ2(1,N=267)=4.14,
p=0.042. The proportion of children with cognitive
impairment using the IQ<70 classiﬁcation was 45.3%,
but only 34.1% of the ASD cases were formally diag-
nosed with ID. The proportion of children with ID
in the CA group was 64%, and 29.9% for the other
ASDs group. ID is by deﬁnition excluded in AS. The
male/female ratio among those with ID was 1.8.
Chromosomal analyses were performed in 122 children
(45.7%), and of these 78 were tested for fragile X. None
of those tested was positive for fragile X. The prevalence
of all medical conditions was 17.2% (95% CI 13.2 to
22.2), including epilepsy. Of the 46 children with a
medical condition, 29 (63%) also had ID. The different
medical conditions are shown in table 2. The prevalence
of epilepsy for all ASD was 7.1% (95% CI 4.6 to 10.8).
Fourteen (73.7%) of those with epilepsy also had ID. The
male/female ratio among those with medical conditions
was 2.3, and among those with epilepsy it was 1.4.
The prevalence of ASD for the 1994–1998 birth
cohort at the end of 2005 was 56.7/10 000 (95% CI 47.6
to 67.4). During the 4-year interval from 2006 to the
end of 2009, more than twice as many children were
diagnosed and the prevalence of ASD doubled. The
comparison of the characteristics within the ASD group
in the two time points (2005 and 2009) is shown in
table 3. The children diagnosed earlier were more often
diagnosed with CA, while those diagnosed later were
more often diagnosed with AS. No difference was found
Table 1 Prevalence of childhood autism, Asperger’s syndrome, other autism spectrum disorders and all autism spectrum
disorders, 95% CIs, male/female ratio, cognitive level and medical conditions in an Icelandic cohort born during 1994–1998
ASD diagnoses Number of cases Rate/10 000 95% CI lower/upper Male/female ratio IQ ≥70 (%) MC (%)
CA 75 33.7 26.9 to 42.3 2.1 21 (28.0) 22 (29.3)
AS 48 21.6 16.3 to 28.6 3 48 (100) 4 (8.3)
Other ASD 144 64.8 55.1 to 76.2 3.2 77 (53.5) 20 (13.9)
All ASD 267 120.1 106.6 to 135.3 2.8 146 (54.7) 46 (17.2)
AS, Asperger’s syndrome; ASD, autism spectrum disorder; CA, childhood autism; MC, medical conditions.
Table 2 Medical conditions in children (n=46) with
childhood autism, Asperger’s syndrome and other autism
spectrum disorders in an Icelandic cohort born during
1994–1998*
CA AS
Other
ASD
All ASD
(%)
Genetic and congenital
syndromes†
8 2 4 14 (5.2)
Chromosomal aberrations‡ 3 0 3 6 (2.2)
Congenital CNS
malformations§
3 1 2 6 (2.2)
Other neurological conditions¶ 6 1 9 16 (6.0)
Epilepsy** 10 0 9 19 (7.1)
*Some children had more than one condition.
Figures in brackets indicate the number of cases:
†Down syndrome [3], Arnold-Chiari malformation [2],
Ehlers-Danlos syndrome [1], homocystinuria [1], neurofibromatosis
[1], Prader-Willi syndrome [1], Saethre-Chotzen syndrome [1],
Smith-Magenis syndrome [1], Sotos syndrome [1], Sturge-Weber
syndrome [1], Turner syndrome [1].
‡inv.9 [p11q12] [2], balanced autosomal rearrangements
t4;14 [p11;q11] [1], microdeletion 3 [p26.3-pter] [1], partial
duplication 8 [q1–q22] [1], partial duplication 20 [q12–q13.13] [1].
§Microcephaly [3], agenesis of the corpus callosum [1],
macrogyria [1], cerebral cyst [1].
¶Cerebral palsy [5], asphyxia/intracranial haemorrhage [3], CNS
infections [3], hearing impairment [2], CNS tumour [1],
extrapyramidal motor disorder [1], vision impairment [1].
**Six children had seizure onset in the first year of life.
AS, Asperger’s syndrome; ASD, autism spectrum disorder; CA,
childhood autism; CNS, central nervous system.
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in the frequency of other ASD whether diagnosed
earlier or later. However, the mean total score on ADI-R
based on verbal cases (n=213) did not differ between
groups, t(211)=0.63, p=0.53, not shown in table 3. More
children diagnosed earlier had an IQ below 70 than
those diagnosed later. This difference was also evident
when comparing mean IQ scores between groups,
t(264)=−3.37, p=0.001, not shown in the table. However,
the proportion of children with a formal diagnosis of ID
did not decrease signiﬁcantly over time (χ2(1, N=267)
=2.45, p=0.117, not shown in the table). Medical condi-
tions were not more common among children diag-
nosed earlier than later in the study period.
DISCUSSION
In the present study, the prevalence of all ASD was
1.2%. This prevalence is in concordance with the higher
end of the range (0.3–1.8%) reported in the 19 newer
surveys published during 2000–2008, according to the
review of Fombonne.2 However, when considering more
recent studies with ASD prevalence of approximately 1%
or higher, our prevalence ﬁgure is at the lower end of
the range from 0.9% to 2.6% (see table 4).3–6 24 25 The
highest prevalences reported, 1.8% and 2.6%, are from
Japan4 and South Korea,6 respectively. It is notable that
the gender ratio in these two studies is relatively low
(2.5–2.8) and similar to the ratio reported in some of
the other studies in table 4.
In the discussion of these studies, care must be taken
as there are considerable differences in the methods
used as well as geographical, cultural and ethnic differ-
ences. The studies from South Thames UK,3
Cambridgeshire UK,5 Goyang City South Korea6 and
Bergen City Norway24 were based on screening for ASD
among children with special educational needs or those
who were on a disability registry, and/or screening
among children in elementary schools, and/or among
local clinicians. In these studies, different adjustments
had to be made to estimate the prevalence due to sam-
pling procedures and different responses and missing
data. In the Autism and Developmental Disabilities
Monitoring Network USA surveillance,25 the prevalence
of ASD was estimated at 0.90% in children aged 8 years,
through a systematic retrospective review by examining
records from areas of 11 states. The prevalence of 1.81%
in the study from Toyota, Japan4 was based on screening
and advice to parents to consult, while the diagnosis was
founded on a clinical interview with parents and obser-
vation of the child.
In the present study, the diagnostic category of CA
represented a relatively small proportion (28%) of the
total number of cases, even if the prevalence is high
(0.34%). This prevalence is 7.7 times higher than that
Table 4 Recent studies on the prevalence of autism spectrum disorders in children estimated at approximately 1% or higher
Study and location
Age
groups Method
Number of clinically
verified cases
Target
population
Prevalence
%
Male/female
ratio
Baird (2006)3 UK 9–10 Records/Survey 158 56 946 1.16* 3.3
Kawamura (2008)4 Japan 1–7 Clinical 228 12 589 1.81† 2.8
ADDM (2009)25 USA 8 Records NA 307 790 0.90‡ 3.2–7.6
Baron-Cohen (2009)5 UK 5–9 Records/Survey NA 8824 1.57* Not reported
Posserud (2010)24 Norway 7–9 Survey 14 6609 0.87* Not reported
Kim (2011)6 South-Korea 7–12 Records/Survey 201 55 266 2.64* 2.5
Present study Iceland 11–15 Clinical 267 22 229 1.20† 2.8
*Estimated prevalence taking non-responders into consideration.
†Calculated from raw numbers.
‡An overall average across 11 ADDM sites.
ADDM, Autism and Developmental Disabilities Monitoring Network, USA; NA, not applicable.
Table 3 Icelandic children born during 1994–1998 with autism spectrum disorders diagnosed until the end of 2005
compared with those diagnosed during 2006–2009 with respect to diagnostic subtypes, gender, cognitive level, medical
conditions and epilepsy
2005 n=126 (%) 2009 n=141 (%) Rate ratio 95% CI lower/upper p Value
CA 49 (38.9) 26 (18.4) 2.11 1.40 to 3.18 0.0002
AS 13 (10.3) 35 (24.8) 0.42 0.23 to 0.75 0.002
Other ASD 64 (50.8) 80 (56.7) 0.90 0.72 to 1.12 0.331
Males 96 (76.2) 101 (71.6) 1.06 0.92 to 1.23 0.398
IQ ≥70 60 (47.6) 86 (61.0) 0.78 0.62 to 0.98 0.028
All MCs 26 (20.6) 20 (14.2) 1.45 0.86 to 2.47 0.163
Epilepsy* 13 (10.3) 6 (4.3) 2.42 0.95 to 6.19 0.054
*Subcategory of MCs.
AS, Asperger’s syndrome; ASD, autism spectrum disorders; CA, childhood autism; MCs, medical conditions.
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reported in the ﬁrst study on autism published in
Iceland26 and almost four times that reported in a more
recent study.27
None of the 19 studies selected by Fombonne2 were
included in a review on medical condition in ASD popu-
lation samples,7 and none of the studies in table 4
reported on medical conditions, except for the present
one. In the above review, the rate of medical conditions
varied from 8% to 25% in studies published between
1996 and 2007.7 A comparison of the proportion of
medical conditions found in the present study with
the ﬁndings of other studies is difﬁcult because a gener-
ally accepted deﬁnition of the phenomenon is lacking.7
Our estimate of 17.2% may seem high, considering
how a large proportion (65.9%) of our ASD cases did
not have diagnosed ID.28 No case with fragile X was
identiﬁed, although the literature predicts fragile X to
be in the range of 2–8% with autism when DNA testing
is utilised.29
Epilepsy in our ASD group was associated with ID and
the female gender, as demonstrated in a meta-analysis.30
The lifetime prevalence of epilepsy for all ASD in the
present study was 7.1%, which is low compared with
other studies on the subject.31 32 It should be noted that
the follow-up in the hospital registry, and thus the regis-
tration of medical conditions, was up to the end of 2009
when the children were 11–15 years old. In this context,
it is of paramount importance to distinguish between
studies on autism in adulthood on the one hand31 and
studies on all ASD in childhood on the other.32 In fact,
the literature on the incidence and prevalence of epi-
lepsy is sparse in relation to high ASD prevalence.
In a 4-year period, from the end of 2005 to the end of
2009, the prevalence of ASD in the cohort studied
doubled, moving from 0.6% to 1.2%. This increase
cannot be explained by immigration to Iceland, con-
ﬁrmed by the National Registry,22 and migration of
people from one part of the country to another is irrele-
vant since the area studied and the whole country are the
same. As expected, children diagnosed earlier (by 2005)
were more likely to have CA than AS and were generally
more impaired than those diagnosed later (2006–2009),
although the groups did not differ regarding the fre-
quency of ID and medical conditions. In order to
examine symptom severity from another angle than diag-
nostic classiﬁcation, we compared the earlier and later
diagnosed groups on ADI-R total score. This comparison
did not reveal differences between groups. High scores
on ADI-R for those diagnosed later indicate serious autis-
tic symptoms, possibly in association with co-occurring
developmental and psychiatric disorders. Another point
of interest is that the number of boys did not increase,
contrary to what is suggested by some investigators.33 One
interpretation of these results is simply that as the cohort
studied grows older, more girls are identiﬁed with ASD,34
and because girls with ASD are more likely to be cogni-
tively impaired, it would counteract the predicted trend
for fewer children with co-occurring ID as the prevalence
of ASD increases. Comparing the distribution of boys and
girls in the group of children with ID (n=91) diagnosed
earlier or later with ASD revealed some support for this
hypothesis, as the gender ratio was 2.8 and 1.2, respect-
ively, although this difference fell short of statistical
signiﬁcance.
Of our ASD cases, 54.7% were classiﬁed with an IQ
of 70 or above. This proportion ranged from 30% to
74.2% in the studies selected by Fombonne,2 where IQ
data were reported (13/19). The studies in table 4,
which present comparable data, show this proportion
to be from 44% to 66.4%.3 4 These ﬁgures indicate
that as the prevalence of ASD increases, the proportion
of children with cognitive impairment decreases.
However, important as the classiﬁcation of cognitive
level above or below IQ 70 may be for comparing epi-
demiological samples with ASD, it should not be over-
looked that IQ<70 simply serves as a proxy for ID. For
instance, it is possible to arrive at a full-scale score on a
Wechsler test of IQ below 70 in various ways, notably
when severe language impairments or non-verbal learn-
ing disabilities are present. From this perspective, there
is a notable difference between the proportion of chil-
dren with IQ<70 (45.3%) and the proportion receiving
a formal diagnosis of ID (34.1%) in the present study.
Thus, the IQ<70 classiﬁcation may provide an inaccur-
ate estimate of how many individuals actually have ID
in addition to ASD.
In the present study, case ﬁnding was based on the
presence of ASD in the records at tertiary level services,
and hence prospective screening identifying potential
cases followed by clinical examination did not take
place. Thus, the clinical source of the data indicates that
the prevalence reported should be regarded as the
minimum ﬁgures. However, the prevalence of ASD
found is based on the exact number of clinically con-
ﬁrmed cases and deﬁnite number of the population
derived from a population register of a whole nation.
Also, based on record linkage, co-occurring medical
conditions were obtained for ASD cases from electronic
hospital records. Nevertheless, this follow-up ended
when the children were 11–15 years of age and other
conditions, for example, epilepsy, may be diagnosed
later during their lifetime. The population is well
deﬁned and relatively homogeneous. Good record
keeping, easy access to healthcare, education free of
charge, and the comprehensive social system have all
ensured efﬁcient case ﬁnding at tertiary institutions,
whose purpose is to serve the diagnostic and counselling
needs of children with serious developmental disorders.
The referral and diagnostic process in the country has
been fairly standardised and is relatively transparent,
compared with larger societies where a multitude of
record sources is to be expected, behind which there
may be widely different diagnostic practices. Only two
tertiary instances offered diagnostic services for ASD
and these have worked in close cooperation regarding
diagnostic procedures. ADI-R was used for 94% of
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children by qualiﬁed clinicians; all had formal cognitive
or developmental testing and consensus diagnoses were
reached within an interdisciplinary team. In addition,
the majority of children diagnosed during their early
preschool years were reassessed before entering elemen-
tary school.
CONCLUSION
The number of clinically veriﬁed cases is larger than in
previous studies, yielding a prevalence rate of ASD on a
similar level as found in recent non-clinical studies. The
tertiary level of services diagnosed a fair number of ASD
cases; however, it may be considered a public-health
issue of how many children are diagnosed after they
enter the elementary school system.
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